Citius Pharmaceuticals (CTXR) Proxy Filing summary

Voting matters and shareholder proposals

• Seven directors are nominated for election to serve until the 2027 annual meeting or until successors are elected and qualified.

• Ratification of Wolf & Company, P.C. as the independent auditor for the fiscal year ending September 30, 2026 is proposed.

• Additional business may be transacted as may properly come before the meeting or any adjournment.

Board of directors and corporate governance

• The board recommends voting in favor of all director nominees and the auditor ratification.

Audit committee and external auditor matters

• Wolf & Company, P.C. is proposed for ratification as the independent registered public accounting firm for the next fiscal year.